Biased Ligands. Better Drugs.

Press Releases

8/11/15 - Trevena Reports Second Quarter 2015 Financial Results and Provides a Corporate Update

Trevena, Inc., today announced financial results for the quarter ended June 30, 2015 and provided an update regarding its ongoing clinical programs. Read More

8/4/15 - Trevena CEO to Present at the 2015 Wedbush PacGrow Healthcare Conference
Trevena, Inc., today announced that Maxine Gowen, Ph.D., chief executive officer, will present a company overview at the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015 at 3:40 p.m. EDT in New York. Read More

7/20/15 - Trevena Appoints Yacoub Habib as Senior Vice President, Business Development and Corporate Planning
Trevena, Inc., today announced the appointment of Yacoub Habib, Ph.D., M.B.A., as senior vice president, business development and corporate planning. Read More

6/29/15 - Trevena Added to Russell 3000®, Russell 2000®, and Russell Global Indexes
Trevena, Inc., today announced it was added to the Russell 3000®, Russell 2000®, and Russell Global Indexes when the Russell Investment Group reconstituted its family of U.S. indexes after the stock market close on June 26, 2015. Read More

6/18/15 - Poster Presentation of Data for Delta Receptor Compound TRV250 at American Headache Society 57th Annual Scientific Meeting
Trevena, Inc., today announced that data highlighting its preclinical TRV250 program will be presented in a poster at the American Headache Society 57th Annual Scientific Meeting being held in Washington D.C., June 18 – 21, 2015. Read More

6/17/15 - Trevena CEO to Present at the 2015 JMP Securities Life Sciences Conference
Trevena, Inc., today announced that Maxine Gowen, Ph.D., its chief executive officer, will present a company overview at the 2015 JMP Securities Life Sciences Conference on Wednesday, June 24, 2015 at 3:30 p.m. EDT in New York. Read More

6/2/15 - Trevena Granted Key U.S. Composition of Matter Patent for TRV734
Trevena, Inc., today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 9,044,469, “Opioid Receptor Ligands and Methods of Using and Making Same.” Read More

5/28/15 - Trevena CEO to present at the Jefferies 2015 Global Healthcare Conference
Trevena, Inc., today announced Maxine Gowen, Ph.D., its chief executive officer, will present a company overview at the Jefferies 2015 Global Healthcare Conference on Wednesday June 3, 2015 at 3:00 p.m. EDT in New York. Read More

5/14/15 - Trevena Announces Presentation of Preclinical Data for Delta Receptor Compound TRV250 at International Headache Congress
Trevena, Inc. (NASDAQ: TRVN), today announced that data highlighting its preclinical TRV250 program will be presented in an oral presentation at the International Headache Congress being held in Valencia, Spain, May 14-17, 2015. Read More

5/7/15 - Trevena Reports First Quarter 2015 Financial Results and Provides a Corporate Update
Trevena, Inc. (NASDAQ: TRVN), today announced financial results for the quarter ended March 31, 2015 and provided an update regarding its ongoing clinical programs. Read More

5/4/15 - Trevena Appoints Carrie Bourdow as Chief Commercial Officer
Trevena, Inc. (NASDAQ: TRVN), today announced the appointment of Carrie L. Bourdow as senior vice president and chief commercial officer, effective immediately. Read More

4/8/15 - Trevena CEO to present at the 14th Annual Needham Healthcare Conference
Trevena, Inc. (NASDAQ: TRVN), today announced Maxine Gowen, Ph.D., its chief executive officer, will present a company overview at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 10:00 a.m. EDT in New York. Read More

3/18/15 - Trevena Reports Full Year 2014 Financial Results
Trevena, Inc. (NASDAQ: TRVN), today announced financial results for the fourth quarter and year ended December 31, 2014. Read More

3/18/15 - Trevena CMO to Present at the BioCentury 22nd Annual Future Leaders in the Biotech Industry conference
Trevena, Inc. (NASDAQ: TRVN), today announced David Soergel, M.D., its chief medical officer, will present a company overview at the BioCentury 22nd Annual Future Leaders in the Biotech Industry conference on Friday March 20, 2015 at 3:00 p.m. EDT in New York. Read More

3/11/15 - Trevena to Host Conference Call on March 18th to Discuss Full Year 2014 Financial Results
Trevena, Inc. (NASDAQ: TRVN), today announced that it will host a conference call on Wednesday, March 18, 2015 at 8:30 a.m. Eastern Time to discuss corporate updates and financial results for the year ended December 31, 2014. Read More

3/9/15 - Trevena completes interim analysis and announces plans for ongoing Phase 2b BLAST-AHF trial of TRV027 in acute heart failure
Trevena, Inc. (NASDAQ: TRVN), today announced its plans for the continuation of the BLAST-AHF trial – a double-blind placebo-controlled study of TRV027 in patients with acute heart failure (AHF) – following the recent completion of the pre-specified interim analysis. Read More

News Archive

Copyright © Trevena, Inc.